Fresenius Kabi has obtained the Food and Drug Administration’s permission for its citrate-free adalimumab biosimilar Idacio for use in the treatment of chronic autoimmune diseases for all eligible ...
Safety, tolerability through 24 months was consistent with 12-month tofacitinib analysis. The approval for Idacio was based on a review of data that showed similar pharmacokinetics, efficacy, safety, ...
The US Food and Drug Administration (FDA) today approved a new autoinjection option for adalimumab-adbm (Cyltezo), a biosimilar to AbbVie's adalimumab (Humira), ahead of Cyltezo's commercial launch on ...
The Food and Drug Administration has designated Celltrion’s Yuflyma (adalimumab-aaty), as an interchangeable biosimilar to Abbvie's Humira (adalimumab). Yuflyma is a high-concentration (100mg/ml) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback